The time course of drug effects

Pharmaceutical Statistics

Volumn 8, Issue 3, 2009, Pages 176-185

  Al Sallami, Hesham S ^a   Pavan Kumar, Venkata V ^a   Landersdorfer, Cornelia B ^b   Bulitta, Jurgen B ^b   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Pharmacometrics

Indexed keywords

DRUG;

DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG RECEPTOR BINDING; DRUG SAFETY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; REVIEW; SINGLE DRUG DOSE; STATISTICAL MODEL; TREATMENT DURATION;

ANIMALS; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 73349102808     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.393     Document Type: Review

References (31)

1. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. Journal of Pharmacokinetics and Pharmacodynamics 2006; 33(3):227-279.
2. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA et al. Model-based drug development. Clinical Pharmacology Therapeutics 2007; 82(1):21-32.
3. Ette EI, Williams PJ, editors. Pharmacometrics: The Science of Quantitative Pharmacology. Wiley: Hoboken, NJ, 2007.
4. Holford N. Clinical pharmacokinetics and pharmacodynamics: the quantitative basis for therapeutics. In: Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics (3rd edn), Melmon KL, Morrelli HF, Nierenberg DW, Hoffman BB (eds). McGraw-Hill: New York, 1992.
5. Schoenwald R. Basic principles. In: Pharmacokinetics in Drug Discovery and Development, Schoenwald R (ed.). CRC Press: New York, 2002.
6. Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist. Technomic Publishing Company Inc: Pennsylvania, 1993.
7. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacology and Therapeutics 1982; 16(2):143-166.
8. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clinical Pharmacology and Therapeutics 1979; 25(3):358-371.
9. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceutics 1993; 21(4):457-478.
10. Krzyzanski W, Jusko WJ. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. Journal of Pharmacokinetics and Biopharmaceutics 1998; 26(4):385-408.
11. Levy G. Kinetics of pharmacologic effects. Clinical Pharmacology and Therapeutics 1966; 7(3):362-372.
12. Piergies AA, Ruo TI, Jansyn EM, Belknap SM, Atkinson Jr AJ, Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clinical Pharmacology and Therapeutics 1987; 42(1):107-112.
13. Edeki T, Johnston A, Li Kam Wa E, Turner P. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing. International Journal of Clinical Pharmacology and Therapeutics 1994; 32(3):142- 146.
14. Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K, Hori R. Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. Journal of Pharmacology and Experimental Therapeutics 1985; 235(2):513-520.
15. Galeazzi RL, Benet LZ, Sheiner LB. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clinical Pharmacology and Therapeutics 1976; 20(3):278-289.
16. Evans MA, Shanks CA, Brown KF, Triggs EJ. Pharmacokinetic and pharmacodynamic modelling with pancuronium. European Journal of Clinical Pharmacology 1984; 26(2):243-250.
17. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clinical Pharmacology and Therapeutics 1994; 56(4):406-419.
18. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. British Journal of Clinical Pharmacology 1998; 45(3):229-239.
19. Slayter KL, Ludwig EA, Lew KH, Middleton Jr E, Ferry JJ, Jusko WJ. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics 1996; 59(3):312-321.
20. Cleton A, de Greef HJ, Edelbroek PM, Voskuyl RA, Danhof M. Application of a combined 'effect compartment/indirect response model' to the central nervous system effects of tiagabine in the rat. Journal of Pharmacokinetics and Biopharmaceutics 1999; 27(3):301-323.
21. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clinical Pharmacology and Therapeutics 1996; 59(6):636-646.
22. Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. Journal of Pharmacology and Experimental Therapeutics 1995; 274(2):921-927.
23. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics 1981; 6(6):429-453.
24. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metabolism and Disposition 2003; 31(5):510-518.
25. Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annual Review of Pharmacology and Toxicology 2007; 47:357-400.
26. Food and Drug Administration. Challenge and Opportunity on the Critical Path to New Medical Products, 2004.
27. Mould D. Developing models of disease progression. In: Pharmacometrics: The Science of Quantitative Pharmacology, Ette E, Williams P (eds). Wiley: New Jersey, 2007.
28. Chan PL, Holford NH. Drug treatment effects on disease progression. Annual Review of Pharmacology and Toxicology 2001; 41:625-659.
29. Holford N, Mould D, Peck C. Disease progression models. In: Principles of Clinical Pharmacology, Atkinson A (ed.). Academic Press: New York, 2001.
30. Holford N, editor. Modelling Disease Progression. Population Approach Group Europe (PAGE): Copenhagen, Denmark, 2007.
31. Kimko HC, Duffull SB. Simulation for Designing Clinical Trials. Marcel Dekker Inc: New York, 2003.